A Phase 1 interventional study of Milvexian and 4-Factor Prothrombin Complex Concentrate (4F-PCC) in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-15.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to evaluate the reversal of the anticoagulant effects of milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa (rFVIIa) in healthy participants as measured by changes from baselines of the coagulation testing parameters (activated partial thromboplastin time [aPTT] and thrombin generation assay [TGA]).
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive two oral doses of milvexian (on Days 1 to 3), one in the morning and one in the evening. On Day 4, participants will only receive the morning dose of milvexian. On Day 4, four hours after the morning dosing of milvexian, each participant will receive an intravenous (IV) infusion of 4-Factor Prothrombin Complex Concentrate (4F-PCC) or matching placebo as per the treatment sequence AB and BA; in treatment period 1 and treatment period 2 where Treatment A=Dose 2 of milvexian + Dose 1 of 4F-PCC; Treatment B=Dose 2 milvexian + Placebo. A washout period of 14 days to 21 days will be maintained between each treatment period 1 and 2.
Drug: Milvexian · Biological: 4-Factor Prothrombin Complex Concentrate (4F-PCC) · Biological: Placebo matching to 4F-PCC
Participants will receive an oral dose of milvexian in morning in fed state on Day 1 and IV injection of Recombinant Human Factor VIIa (rFVIIa) or placebo matching to rFVIIa on Day 1 after 4 hours post morning milvexian dose in the following treatment sequence: DEF1, EF1D, F1DE, EDF1, F1ED and DF1E; in treatment period 1, treatment period 2 and treatment period 3 respectively where Treatment D=Dose 1 of milvexian +Dose 1 of rFVIIa; Treatment E=Dose 3 of milvexian+Dose 1 of rFVIIa; Treatment F1=Dose 3 of milvexian+Placebo; Treatment F2=Dose 1 of milvexian+Placebo. A washout period of 4 days will be maintained between each treatment period 1, 2 and 3.
Drug: Milvexian · Biological: Recombinant Human Factor VIIa (rFVIIa) · Biological: Placebo matching to rFVIIa
Participants will receive an oral dose of milvexian in morning in fed state on Day 1 and IV injection of rFVIIa or placebo matching to rFVIIa on Day 1 after 4 hours post morning milvexian dose in the following treatment sequence: DEF2, EF2D, F2DE, EDF2, F2ED and DF2E; in treatment period 1, treatment period 2 and treatment period 3 respectively where Treatment D=Dose 1 of milvexian+Dose 1 of rFVIIa; Treatment E=Dose 3 of milvexian+Dose 1 of rFVIIa; Treatment F1=Dose 3 of milvexian+Placebo; Treatment F2=Dose 1 of milvexian+Placebo. A washout period of 4 days will be maintained between each treatment period 1, 2 and 3.
Drug: Milvexian · Biological: Recombinant Human Factor VIIa (rFVIIa) · Biological: Placebo matching to rFVIIa
Milvexian will be administered orally.
Also known as: BMS-986177, JNJ-70033093
4F-PCC will be administered intravenously.
rFVIIa will be administered intravenously.
Placebo matching to 4F-PCC will be administered intravenously.
Placebo matching to rFVIIa will be administered intravenously.
Part 1: Change from Baseline in Activated Partial Thromboplastin Time (aPTT)
The aPTT measures the time it takes plasma to clot when exposed to substances that activate the contact factors, which assesses the intrinsic and common pathways of coagulation.
Time frame: Baseline, Day 4
Part 2: Change from Baseline in aPTT
The aPTT measures the time it takes plasma to clot when exposed to substances that activate the contact factors, which assesses the intrinsic and common pathways of coagulation.
Time frame: Baseline, Day 1
Part 1: Change from Baseline in Endogenous Thrombin Potential (ETP) (Thrombin Generation Assay [TGA] Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the ETP (TGA parameter). The ETP assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro and anti-coagulant forces in plasma.
Time frame: Baseline, Day 4
Part 1: Change from Baseline in Lag Time (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the lag time (TGA parameter). The lag time is defined as the time needed until thrombin is generated.
Time frame: Baseline, Day 4
Part 1: Change from Baseline in Peak Thrombin (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the peak thrombin (TGA parameter). The peak thrombin is defined as the maximal effect on thrombin generation.
Time frame: Baseline, Day 4
Part 1: Change from Baseline in Time to Peak Thrombin (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the time to peak thrombin (TGA parameter). The time to peak thrombin is defined as the time required to reach maximal effect on thrombin generation.
Time frame: Baseline, Day 4
Part 2: Change from Baseline in ETP (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the ETP (TGA parameter). The ETP assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro and anti-coagulant forces in plasma.
Time frame: Baseline, Day 1
Part 2: Change from Baseline in Lag Time (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the lag time (TGA parameter). The lag time is defined as the time needed until thrombin is generated.
Time frame: Baseline, Day 1
Part 2: Change from Baseline in Peak Thrombin (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the peak thrombin (TGA parameter). The peak thrombin is defined as the maximal effect on thrombin generation.
Time frame: Baseline, Day 1
Part 2: Change from Baseline in Time to Peak Thrombin (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the time to peak thrombin (TGA parameter). The time to peak thrombin is defined as the time required to reach maximal effect on thrombin generation.
Time frame: Baseline, Day 1
Number of Participants with Treatment-Emergent Adverse Events (TEAE) as a Measure of Safety and Tolerability
Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) with onset or worsening on or after date of first dose of study treatment.
Time frame: Part 1: Up to 74 Days; Part 2: Up to 25 Days
Number of Participants with TEAEs of interest
Number of participants with TEAEs of interest will be reported. TEAEs associated with the following situations are considered as TEAEs of interest: bleeding, thromboembolic events (TEs) and liver injury.
Time frame: Part 1: Up to 74 Days; Part 2: Up to 25 Days
Parts 1 and 2: Change From Baseline in Pulse Rate
Changes from baseline in pulse rate will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Changes from baseline in SBP and DBP will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in QTc Interval
Change from baseline in QT interval corrected for heart rate (QTc interval) using Fridericia method will be measured by ECG.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change from Baseline in Heart Rate (HR)
Change from baseline in HR will be measured by ECG.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change from Baseline in QRS Interval
Change from baseline in QRS interval will be measured by ECG
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change from Baseline in PR Interval
Change from baseline in PR interval will be measured by ECG.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in QT Interval
Change from baseline in QT interval will be measured by ECG.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Hematology Parameter: Platelet Count
Change from baseline in hematology parameter (platelet count) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Hematology Parameter: Red Blood Cell (RBC) count
Change from baseline in hematology parameter (RBC count \[Unit: Cells per liter\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Hematology Parameter: Hemoglobin (Hb)
Change from baseline in hematology parameter (Hb \[Grams per deciliter\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Hematology Parameter: Hematocrit
Change from baseline in hematology parameter (Hematocrit) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)
Change from baseline in hematology parameter (MCV \[Femtoliter\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Change from baseline in hematology parameter (MCH \[Picogram\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Hematology Parameter: Percentage of Reticulocytes
Change from baseline in hematology parameter (Percentage of reticulocytes) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Hematology Parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
Change from baseline in hematology parameters (Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils \[Unit: Giga cells per liter\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Coagulation Parameter: Activated Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT)
Change from baseline in coagulation parameter (aPTT and PT \[Unit: Seconds\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides
Change from baseline in serum chemistry parameters (Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Sodium, Blood urea nitrogen \[BUN\], Cholesterol, High density Lipoprotein \[HDL\], Low density lipoprotein \[LDL\], Triglycerides \[Unit: Millimole per Liter\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: ALT, AST, GGT, LDH, Alkaline phosphatase, CPK
Change from baseline in serum chemistry parameters (Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\], Gamma-glutamyl transferase \[GGT\], Lactic acid dehydrogenase \[LDH\], Alkaline phosphatase, Creatine phosphokinase \[CPK\] \[Unit: International units per Liter\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Amylase
Change from baseline in serum chemistry parameters (Amylase \[Unit: Units per liter\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Lipase
Change from baseline in serum chemistry parameters (Lipase \[Unit: Units per liter\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Total Bilirubin, Creatinine and Uric Acid
Change from baseline in serum chemistry parameters (Total bilirubin, Creatinine and Uric acid \[Unit: Micromoles per Liter\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Total Protein and Albumin
Change from baseline in serum chemistry parameters (Total protein and Albumin \[Unit: Gram per Liter\]) will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Urinalysis Parameter: Specific Gravity
Change from baseline in urinalysis parameter (Specific gravity) tests will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Parts 1 and 2: Change From Baseline in Urinalysis Parameter: pH
Change from baseline in urinalysis parameter (pH) tests will be assessed.
Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days
Part 1: Mean Trough Plasma Concentration of Milvexian at Steady State (Ctrough)
Mean trough plasma concentration of milvexian at steady state will be reported.
Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose
Part 1 and Part 2: Maximum Observed Analyte Concentration (Cmax) of Milvexian
Cmax is the maximum observed analyte concentration.
Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose; Part 2: 0.25, 2, 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 1 and Part 2: Time to Reach Maximum Plasma Concentration (Tmax) of milvexian
Tmax is defined as actual sampling time to reach the maximum observed analyte concentration.
Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose; Part 2: 0.25, 2, 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Parts 1 and Part 2: Elimination Half-Life (t1/2) of Milvexian
t1/2 elimination half-life means time measured for the plasma concentration to decrease by 1 half to its original concentration of milvexian.
Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose; Part 2: 0.25, 2, 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Dosing Interval (AUC [0-t]) of Milvexian
Area under the plasma concentration versus time curve from time zero to dosing interval of milvexian.
Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose
Part 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of Milvexian
Area under the plasma concentration versus time curve from time zero to infinity with extrapolation of the terminal phase of milvexian.
Time frame: Part 2: 0.25, 2, 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 1 and Part 2: Area Under Plasma Concentration From Time Zero to the Last Quantifiable Concentration (AUC [0-last]) of Milvexian
Area under the plasma concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration of milvexian will be assessed.
Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose; Part 2: 0.25, 2, 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 2: Maximum Observed Analyte Concentration (Cmax) of rFVIIa
Cmax is the maximum observed analyte concentration.
Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 2: Time to Reach Maximum Plasma Concentration (Tmax) of rFVIIa
Tmax is defined as actual sampling time to reach the maximum observed analyte concentration.
Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 2: Elimination Half-Life (t1/2) of rFVIIa
t1/2 elimination half-life means time measured for the plasma concentration to decrease by 1 half to its original concentration of rFVIIa.
Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of rFVIIa
Area under the plasma concentration versus time curve from time zero to infinity with extrapolation of the terminal phase of rFVIIa.
Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 2: Area Under Plasma Concentration From Time Zero to the Last Quantifiable Concentration (AUC [0-last]) of rFVIIa
Area under the plasma concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration of rFVIIa will be assessed.
Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 2: Systemic Clearance (CL) of rFVIIa
CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose will be estimated by dividing the total administered dose by the area under the plasma concentration-time curve from time zero to infinite time (AUC \[0-infinity\]).
Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 2: Volume of distribution (Vz) of rFVIIa
The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose
Part 1 and Part 2: Change from Baseline in aPTT
Change from baseline in aPTT will be reported.
Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2
Part 1 and Part 2: Change from Baseline in ETP (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the ETP (TGA parameter). The ETP assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro and anti-coagulant forces in plasma.
Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2
Part 1 and Part 2: Change from Baseline in Lag Time (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the lag time (TGA parameter). The lag time is defined as the time needed until thrombin is generated.
Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2
Part 1 and Part 2: Change from Baseline in Peak Thrombin (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the peak thrombin (TGA parameter). The peak thrombin is defined as the maximal effect on thrombin generation.
Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2
Part 1 and Part 2: Change from Baseline in Time to Peak Thrombin (TGA Parameter)
The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the time to peak thrombin (TGA parameter). The time to peak thrombin is defined as the time required to reach maximal effect on thrombin generation.
Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2
Percent Change from Baselines in aPTT
Percent change from baseline in aPTT will be reported.
Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
No publications or documents are linked to this record.
Ran from Jul 2020 to primary completion in Jun 2023, 34 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Four-factor Prothrombin Complex Concentrate
Janssen Research & Development, LLC →